Delivery Order SPE2DB20D2104-SPE2DB22FS38H
- Not listed
- This federal contract award is for the delivery of the pharmaceutical product Trulicity 1.5 mg/0.5 ml pen 0.5 ml to the Defense Logistics Agency (DLA). The contract was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has a ceiling value of $6,686.19 and an ultimate completion date of April 29, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award is for the delivery of the pharmaceutical product Trulicity 1.5 mg/0.5 ml pen (0.5 ml) to the Defense Logistics Agency (DLA). The $3,387.24 delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a firm fixed price and does not utilize any set-aside designations, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award is for the delivery of the pharmaceutical product Trulicity 1.5 mg/0.5 ml pen 0.5 ml to the Defense Logistics Agency (DLA). The $1,451.40 contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a completion date of May 24, 2023 and is a firm fixed price delivery order. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds a significant $999,999,999 Indefinite Delivery Contract...
- This federal contract award is for the delivery of the pharmaceutical product Trulicity 1.5 mg/0.5 ml pen 0.5 ml to the Medical Supply Chain division of the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $2,820.90 and an ultimate completion date of December 1, 2023. It was awarded on November 30, 2023 as a firm fixed-price delivery order. The contract is not designated...
- This federal contract award is for the delivery of Trulicity 1.5 mg/0.5 ml pens to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military and veteran...
- This federal contract award is for the supply of the pharmaceutical product Trulicity 1.5 mg/0.5 ml pen 0.5 ml to the Defense Logistics Agency (DLA). The contract, valued at $26,455.56, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a completion date of May 10, 2024 and is a firm fixed-price delivery order. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that...
- This federal contract award is for the delivery of the pharmaceutical product Trulicity (3 mg/0.5 ml pen, 0.5 ml) to the Medical Supply Chain division of the Defense Logistics Agency (DLA), a defense agency. The $14,806.24 fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a period of performance through February 12, 2024 and was not designated as a set-aside award. Amerisourcebergen holds a significant...
- This federal contract award is for the delivery of 4560123971 units of Trulicity 1.5 mg/0.5 ml pen 0.5ml to the Defense Logistics Agency (DLA). The contract, awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., has a ceiling value of $3,761.54 and a performance period ending on March 3, 2023. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award is for the delivery of pharmaceutical products, specifically Trulicity 3 mg/0.5 ml pens, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distribution company. The contract has a ceiling value of $1,015.98 and a period of performance through May 9, 2024. It is a firm-fixed-price delivery order contract, without any set-aside designation....
- This federal contract award is for the delivery of the pharmaceutical product Trulicity 0.75 mg/0.5 ml pen 0.5 ml to the Defense Logistics Agency (DLA). The contract, awarded to prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., has a ceiling value of $1,708.38 and runs through September 14, 2022. The contract is a Firm Fixed Price Delivery Order and was not set aside for any specific business category. Amerisourcebergen Drug Corp, a major pharmaceutical distributor,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FS38HDelivery Order
This federal contract award is for the delivery of the pharmaceutical product Trulicity 1.5 mg/0.5 ml pen 0.5 ml to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $2,968.48 and was awarded on April 11, 2022 as a firm fixed-price delivery order. There was no set-aside designation for this contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and other critical medical commodities. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 4/11/22 |